Vaishali Pharma Ltd. (VAISHALI) AI Stock Analysis

1 Followers

Vaishali Pharma Ltd.

(NSE:VAISHALI)

Select Model

Rating:62Neutral

Price Target:INR 8.00▲(14.45% Upside)

Action:reiterated

Date:04/22/26

Score driven by robust technical momentum and moderate valuation, tempered by weak financials including profitability declines and negative cash flows; strong revenue growth offers upside potential if margins improve.

Positive Factors

Strong revenue growthSustained ~15% year-over-year revenue growth provides a durable top-line foundation, signaling expanding customer demand or market share. Over months, healthy revenue expansion supports reinvestment in products, absorbs SG&A, and underpins a path back to operating profitability if cost trends stabilize.

Negative Factors

Negative operating and free cash flowMaterial negative operating and free cash flow in 2025 is a durable constraint on the company's ability to self-fund working capital, capex, or growth. Over several months this necessitates external financing or asset sales, increasing cost of capital and reducing strategic flexibility.

Vaishali Pharma Ltd. (VAISHALI) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 951.07M
Dividend Yield: ―
Average Volume (3M): 135.45K
Price to Earnings (P/E): 20.5
Beta (1Y): 0.97
Revenue Growth: 3.08%
EPS Growth: 972.22%
Country: India
Employees: 30
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Vaishali Pharma Ltd. Business Overview & Revenue Model

Company Description

Vaishali Pharma Limited functions as a pharmaceutical enterprise, conducting its business both within India and across global markets. The company's extensive product portfolio encompasses Active Pharmaceutical Ingredients (APIs), covering a broad sp...

How the Company Makes Money

null

Vaishali Pharma Ltd. Financial Statement Overview

Summary

Score reflects strong revenue growth (14.7% FY2025) and solid balance sheet (equity ratio 59.1%, D/E 0.19), offset by weak profitability (EBIT margin -0.4%, net margin 0.8%) and severe cash flow deterioration (FCF -₹197.4M).

Income Statement

42Neutral

Balance Sheet

60Neutral

Cash Flow

27Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	1.08B	1.09B	990.26M	862.80M	696.63M	758.21M
Gross Profit	99.44M	101.35M	102.85M	96.43M	129.19M	80.36M
EBITDA	50.71M	41.14M	32.95M	31.71M	113.59M	86.44M
Net Income	42.80M	41.65M	8.17M	7.19M	66.03M	40.24M
Balance Sheet
Total Assets	0	1.23B	1.10B	799.56M	789.07M	816.24M
Cash, Cash Equivalents and Short-Term Investments	14.30M	14.30M	18.43M	14.57M	124.24M	11.62M
Total Debt	0	188.90M	125.53M	134.92M	147.36M	208.11M
Total Liabilities	-691.15M	542.74M	449.29M	371.16M	383.76M	552.70M
Stockholders Equity	691.15M	691.15M	649.16M	428.39M	405.31M	263.54M
Cash Flow
Free Cash Flow	0	0	-197.36M	2.71M	7.83M	4.54M
Operating Cash Flow	0	0	-194.31M	8.07M	10.80M	13.19M
Investing Cash Flow	0	0	-1.88M	12.03M	2.82M	-8.47M
Financing Cash Flow	0	0	184.91M	-14.16M	-17.32M	4.17M

Vaishali Pharma Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price6.99

Price Trends

50DMA7.86Negative

100DMA7.82Negative

200DMA7.52Negative

Market Momentum

MACD-0.31Negative

RSI42.55Neutral

STOCH60.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VAISHALI, the sentiment is Negative. The current price of 6.99 is below the 20-day moving average (MA) of 7.10, below the 50-day MA of 7.86, and below the 200-day MA of 7.52, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 42.55 is Neutral, neither overbought nor oversold. The STOCH value of 60.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VAISHALI.

Vaishali Pharma Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VAISHALI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PAR	73Outperform	INR 1.39B	11.18	―	―	9.40%	34.12%
IN:VAISHALI	62Neutral	INR 947.70M	20.50	―	―	3.08%	972.22%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:VIVIMEDLAB	42Neutral	INR 464.32M	-0.25	―	―	-39.80%	-452.04%
IN:BIOFILCHEM	41Neutral	INR 494.07M	105.17	―	―	9.31%	-82.71%
IN:LASA	38Underperform	INR 227.96M	-1.28	―	―	-95.17%	50.07%
IN:MANGALAM	37Underperform	INR 463.77M	-1.22	―	―	-2.37%	-92.45%

* General Sector Average

Performance Comparison

IN:VAISHALI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VAISHALI	Vaishali Pharma Ltd.	6.99	-2.64	-27.41%
IN:BIOFILCHEM	Biofil Chemicals & Pharmaceuticals Ltd.	31.13	-8.24	-20.93%
IN:LASA	Lasa Supergenerics Ltd.	4.55	-5.86	-56.29%
IN:MANGALAM	Mangalam Drugs & Organics Ltd.	29.38	-32.11	-52.22%
IN:PAR	Par Drugs and Chemicals Limited	118.11	24.41	26.05%
IN:VIVIMEDLAB	Vivimed Labs Limited	5.55	0.65	13.27%

Vaishali Pharma Ltd. Corporate Events

Vaishali Pharma Adjusts Kesar Pharma Share-Swap Terms to Match Valuation

Jun 18, 2026

Vaishali Pharma clarified a discrepancy identified by the National Stock Exchange of India regarding its preferential allotment of up to 61,23,000 equity shares to Kesar Pharma Limited via a share swap. The original approval was based on acquiring 21...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Apr 22, 2026

Vaishali Pharma Ltd. AI Stock Analysis